Placeholder Banner

BIO Comments on FDA Draft Guidance on Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drugs and Biologics

July 8, 2019

BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drugs and Biologics Guidance for Industry.

BIO welcomes the draft guidance, which establishes a simple and reliable mechanism for identifying submissions with Real-World Data – a new area of regulatory science and policy at FDA.

BIO encourages FDA to consider how Real-World Data (RWD) or Real-World Evidence (RWE) could be used to generate publicly available information, like public summaries, for the research community. BIO also comments on document submissions for Investigational New Drugs (INDs), New Drug Applications (NDAs), or Biologics License Applications (BLAs). Finally, BIO’s provides recommendations on how to better promote the collection and utilization of RWD or RWE.

 

Download Full Comments Below
FINAL BIO Letter Submitting Documents Using RWE 7-8-19
Read the full comments below
Discover More
March 18, 2020 FDA Docket No: FDA-2019-D-4964: FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Dear Sir/Madam: BIO thanks FDA for developing this additional guidance on…
March 15, 2020 Re: Docket No. FDA–2019-D-4752: FDA Draft Guidance, Pediatric Study Plans for Oncology Drugs: Questions and Answers BIO appreciates FDA’s efforts to develop a document that outlines questions and answers pertaining to Pediatric…
In the wake of the COVID-19 outbreak, the Biotechnology Innovation Organization (BIO) joins 111 industry groups across sectors in a letter to federal, state and local lawmakers supporting uniform definitions of "critical infrastructure" as outlined…